The Brazilian health regulator Anvisa banned the Voy platform on June 26, 2026 [1], to curb the sale of unregulated weight-loss pens.
This crackdown comes as a surge in demand for GLP-1 analog injectables, such as tirzepatide and semaglutide, leads to an increase in illegal imports and unsafe distribution channels. The regulator is prioritizing patient safety as consumers increasingly seek rapid weight loss through non-medical platforms.
Many of these injectable pens originate from Paraguay [3]. Anvisa has moved to prohibit these unregulated imports because they bypass national safety standards and medical oversight. The agency aims to prevent the distribution of medications that have not been verified for quality or authenticity within the Brazilian market [3].
Medical experts are also warning about the physical consequences of the rapid fat loss associated with these drugs. Reports published on June 29, 2026, highlight that the speed of weight loss can lead to significant facial flaccidity [2]. This effect occurs when the skin cannot adapt quickly enough to the loss of subcutaneous fat, creating a sagging appearance in the face [2].
Beyond aesthetic concerns, the use of these pens without professional supervision poses severe health risks. Anvisa said the prohibition of platforms like Voy is necessary to ensure that patients only access these potent medications under strict clinical guidance and through licensed pharmacies [1].
Consumers are urged to avoid purchasing medications from unofficial websites or across borders. The regulator said that the risks of using unverified substances include improper dosing and potential contamination from unregulated manufacturing processes [1].
“Anvisa banned the Voy platform on June 26, 2026”
The Brazilian government's aggressive stance reflects a growing global tension between the high consumer demand for GLP-1 medications and the ability of healthcare systems to regulate their distribution. By targeting both the digital platforms and the physical import routes from neighboring countries, Anvisa is attempting to close a loophole where aesthetic goals override medical safety protocols.